Alembic Pharma rose over 2.5% to Rs.526.75. Its 52-week high and low stands at Rs.588 and Rs.412.40 respectively.

The stock price has shown positive movement on receiving news that its has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for the inspection carried out by them at our API Facility at Karakhadi during the period from 14th May, 2018 to 18th May, 2018.

The  company said, “With this, all our manufacturing facilities for international markets are FDA compliant.”